Events | Today This Week This Month All Events
Interview Notice
Registration Deadline：2023-09-11 11:00
Contact：Xu Peizhi, 18019788613
Media units,
This year marks the 10th anniversary of the establishment of the China (Shanghai) Pilot Free Trade Zone. As the inaugural free trade pilot zone in the nation, the Pilot Free Trade Zone is a tangible testament to Shanghai’s unwavering commitment to pioneering reform, opening-up, innovation, and development. It stands at the forefront of driving high-quality growth within the Chinese economy while injecting substantial positive energy into the global economic recovery.
Seizing this momentous occasion, we will organize the eighth episode of an interview series with the theme of “Promoting High-quality Economic Development” for Chinese and foreign reporters. Scheduled for September 12 (Tuesday), this full-day event will feature insightful conversations with representatives from the automated container terminal of Shanghai Yangshan Port Phase IV, Obio Technology (Shanghai) Corp., Ltd. and Aplos Machines Manufacturing (Shanghai) Co., Ltd. (company profiles attached). The event’s agenda is as follows:
08:15 - 08:30 Gather at 200, Renmin Avenue, for departure
10:30 - 11:30 The automated container terminal of Shanghai Yangshan Port Phase IV
12:30 - 13:00 Working lunch (3888, Canghai Road, Fengxian District)
13:00 - 14:00 Obio Technology (Shanghai) Corp., Ltd. (3888, Canghai Road, Fengxian District)
14:30 - 15:30 Aplos Machines Manufacturing (Shanghai) Co., Ltd.
Kindly reminder: Since Yangshan Port Terminal is a no-fly zone for drones, please do not use drones for aerial photography.
Please kindly inform us of the media unit, the reporter’s name, mobile phone number in an email to touchshanghai@126.com before September 11, 2023.
Contact: Xu Peizhi, 18019788613
Information Office of Shanghai Municipality
September 8, 2023
Company Profiles
1.Shanghai Yangshan Port
Shanghai Yangshan Deepwater Port embarked on its official inauguration on December 10, 2005, with the completion of its phase V section. In recent years, the container transportation operations at Shanghai Port have exhibited a consistent pattern of rapid and stable growth. In the year 2022, the container throughput at Shanghai Port surpassed 47.3 million TEUs, securing its position as the world’s foremost port for the 13th consecutive year. The UNCTAD’s liner shipping connectivity index has consistently placed Shanghai Port at the pinnacle of global rankings for 12 consecutive years. This accomplishment underscores Shanghai Port’s innate strength and remarkable resilience. Furthermore, in the latest Xinhua-Baltic International Shipping Centre Development Index Report, Shanghai has ascended to a prestigious spot among the world’s top three. The primary highlights are as follows:
(1) Digital Transformation
The automated terminal of Yangshan Phase IV has taken pioneering steps by introducing a state-of-the-art digital twin system, heralding the development of an all-encompassing digital operations management platform that spans the entirety of the Shanghai Port and its eight container terminals. This milestone achievement marks the realization of a “three mapping in one” concept, namely electronic waterway mapping, coastline mapping, and berth mapping. Additionally, substantial progress has been made in establishing a comprehensive digital twin base, covering 70 square kilometers within the core section of the Huangpu River and 30 square kilometers in the eastern section of the Suzhou Creek. Furthermore, efforts to expedite the development of digital twin technology within the aviation sector are well underway, aimed at enhancing the intelligence of airport operations and management systems. The coordination of regional ports and shipping infrastructure is progressing methodically, facilitating information sharing and fostering collaborative commerce within the container river-ocean combined transport network along the Yangtze River. In a pioneering feat, the world’s first large-scale intelligent container ship, the “Lotus,” has been successfully built. This vessel boasts intelligent features within its engine room, energy efficiency systems, and navigation capabilities.
(2) Advancements in Intelligence
The Yangshan Deepwater Port Phase V stands as the world’s largest and most automated container terminal. The pivotal technologies pioneered here have found application in more than 10 terminals both domestically and internationally. Yangshan Port’s intelligent heavy trucks have notched up “four remarkable breakthroughs”: from initial road testing to successful demonstration operations, from single-vehicle intelligence to vehicle-road coordination, from independent platform deployment to system-wide integration, and from technology research and development to commercially viable exploration. A total of nearly 200,000 TEUs have been transported. Yangshan Port has further cemented its status as a trailblazer by becoming the first fully paperless port in China for all aspects of container business operations, achieving a 100% paperless operation rate. Global Shipping Business Network (GSBN) has revolutionized the import container document processing landscape, reducing the average processing time from a range of 24-48 hours to under 4 hours. Additionally, the concerted efforts towards the development of the Shanghai International Container Transportation Service Platform (container transport MaaS) have yielded a user-friendly system that offers “one-stop information inquiry” and streamlines “one-stop public services.”
(3) Sustainable Green Initiatives
Since the inception of the innovative to build the shipping center, there has been a steadfast commitment to optimizing port transportation and fostering an eco-friendly energy structure. In terms of the collecting and dispatching system, the proportion of containers transshipped reached 53.5% in 2022, an all-time high record. Furthermore, sea-rail combined transport for containers achieved a total volume of 576,000 TEUs, a year-on-year increase of 38%. In terms of the energy structure, within the domain of non-road mobile machinery, 49% now comprises clean energy and new energy equipment. Additionally, the port area boasts a network of 65 shore power facilities, strategically placed across five distinct types of specialized berths, achieving a coverage rate of 79%. Moreover, Shanghai Ports pioneering LNG ship-to-ship operation has become a standardized practice. In parallel, various green energy projects, including shore power, photovoltaic systems, and wind power, have been systematically rolled out across the port area.
In the future, Shanghai Port is poised to expedite the convergence of informatization, intelligence, and on-site production. This commitment will be realized through a series of pioneering initiatives, including the modernization and revitalization of conventional container terminals and the piloting of smart heavy trucks at Yangshan Port. Furthermore, the port will actively delve into the fusion of cutting-edge technologies such as blockchain, artificial intelligence, and big data, seeking their practical application across port production, operations, and management.
2.Obio Technology (Shanghai) Corp., Ltd.
Obio Technology (Shanghai) Corp., Ltd., founded in March 2013, is a pioneering biotech firm dedicated to advancing the realm of gene therapy. Our core focus includes foundational gene therapy research, the development of gene therapy vectors, gene function investigations, and an array of contract research organization (CRO) services, ranging from drug target exploration to drug efficacy studies. We also offer contract development and manufacturing organization (CDMO) services, including process development and testing, IND-CMC pharmaceutical research, and the GMP production of clinical samples.
Since its inception, the company has been steadfast in its commitment to the ethos of harmonizing resources to serve the life sciences. Guided by core values on customer-centricity, operational efficiency, pursuit of excellence, innovation and breakthroughs, integrity and pragmatism, we have experienced substantial growth and evolved into a cutting-edge enterprise that seamlessly integrates three key developmental dimensions in the realm of gene therapy: gene function basic research services, incubation of cell and gene therapy medications, and commercial-scale production services for clinical-grade cell and gene therapy drugs. Through nearly a decade of relentless dedication, Obio has garnered numerous accolades and qualifications, including recognition as a “Shanghai Science and Technology Little Giant Enterprise,” a “Shanghai Specialized and Sophisticated Enterprise,” a “Shanghai Patent Work Pilot Demonstration Enterprise,” a “Shanghai Enterprise Technology Center,” a “Shanghai Key Service Unicorn Enterprise,” a “Shanghai Customs Innovation Pioneer Demonstration Enterprise,” a “Shanghai Small- and Medium-sized Enterprise Technology Innovation and Quality Service Agency,” a “Pudong New Area Large Enterprise Open Innovation Center,” and a “Pudong New Area Enterprise R&D Institution,” among others. At present, our team comprises over 700 professionals, with over 50% dedicated to technical research and development. More than 30% of our workforce holds master’s degrees or higher qualifications. Our subsidiary companies include Obio Neuron (Shanghai) Biotechnology Co., Ltd., Obio Smart Manufacturing (Shanghai) Gene Technology Co., Ltd., Obio Xinchuang Biotechnology Research and Development (Shanghai) Co., Ltd., and Obio Jiuhe (Shenzhen) Gene Technology Co., Ltd.
With the mission of “Enable Gene Therapy for Better Life,” the company has focused on the research and development of viral vectors and the development of large-scale production processes to foster the development technology of gene therapy vectors. The company specializes in two core technology clusters, namely vector development technology and quality control technology for gene therapy, to establish a large-scale, highly flexible GMP production system suitable for a variety of gene drugs, versatile enough to cater to a wide spectrum of gene-based drugs. Our offerings encompass: 1) Vector products, including plasmids, adeno-associated viruses, and lentiviruses; 2) oncolytic virus products, such as oncolytic herpes viruses and oncolytic pox viruses; 3) comprehensive technical research, process development, and GMP production services catering to cell therapy products, CAR-T therapies.
The company currently boasts a robust network of over 9,000 CRO collaborative partners and nearly 150 CDMO collaborators. We take pride in holding 23 authorized invention patents within our two core technology domains, along with 59 distinct trademark registrations and 6 copyrighted assets. Moreover, we have established a state-of-the-art suite of in-house platforms, including molecular biology, experimental-grade virus vector packaging, cell function research, SPF-level animal experimentation, clinical-grade gene therapy vector and cell therapy process development, and quality control technology research platforms, among others.
Obio boasts an expansive research and development facility spanning over 5,000 square meters, a Gene Therapy Vector GMP Production Center exceeding 10,000 square meters, and a substantial investment of over 1.6 billion yuan to establish Obio Intelli-M. This sprawling, 80,000-square-meter facility is situated in the Lingang New Area of the China (Shanghai) Pilot Free Trade Zone, serving as an intelligent manufacturing precision medical industry hub. Obio Intelli-M project strategically leverages its location near the port to create an industrialized production hub for gene therapy and cell therapy medications. This production center adheres rigorously to international GMP standards, catering to the clinical and trial requirements of various viral and cellular products, as well as enabling commercial drug production. Furthermore, it will feature a cutting-edge detection technology platform for recombinant virus and cell-based drugs, establishing stringent quality benchmarks for related medications. Our platform is uniquely positioned to offer CDMO/CMO services for gene and cell therapy ventures. With world-class infrastructure and a robust GMP quality management system, this platform empowers the acceleration of gene therapy’s clinical applications, reduces drug production costs, enhances the accessibility of gene and cell therapy products, and bridges the domestic gap in this crucial field.
With the introduction and active execution of Shanghai’s 14th Five-Year Development Plan and the ongoing expansion of the “Innovative Medicines” strategic emerging industries in Pudong New Area, Obio remains steadfast in its commitment to delivering specialized services. Our aim is to establish a globally leading gene and cell therapy CXO conglomerate, expediting progress across fundamental research, drug discovery, pharmaceutical research, clinical trials, and commercialization in the field of gene therapy. We are dedicated to advancing the gene therapy industry, ultimately contributing to the enhancement of human health and well-being.
3. Aplos Machines Manufacturing (Shanghai) Co., Ltd.
Aplos Machines Manufacturing (Shanghai) Co., Ltd. is a technology-driven company that specializes in designing and producing mid to high-end CNC machine tools using direct-drive technology. We are dedicated to the field of metal cutting and serve a diverse range of manufacturing industries including civil aviation, mold-making, compressors, engineering machines, medical equipment, semiconductor, and the automotive industry.
Our highly-trained and innovative R&D team consists of over 60 engineers based in Shanghai and Singapore. They are experts in machine structural design, advanced Mechatronic systems, motion control, automation solutions, Industrial IoT, and machining technologies.
At Aplos Machines, we offer a completely new machine tool blueprint to China's manufacturing sector. Our products are engineered to deliver higher efficiency and accuracy, longer lifespan, and the ability to handle heavy cutting, ultra high-speed cutting, and micro-level cutting. We provide a revolutionary metal-cutting solution that caters to the evolving needs of the manufacturing industry.
This year marks the 10th anniversary of the establishment of the China (Shanghai) Pilot Free Trade Zone. As the inaugural free trade pilot zone in the nation, the Pilot Free Trade Zone is a tangible testament to Shanghai’s unwavering commitment to pioneering reform, opening-up, innovation, and development. It stands at the forefront of driving high-quality growth within the Chinese economy while injecting substantial positive energy into the global economic recovery.
Seizing this momentous occasion, we will organize the eighth episode of an interview series with the theme of “Promoting High-quality Economic Development” for Chinese and foreign reporters. Scheduled for September 12 (Tuesday), this full-day event will feature insightful conversations with representatives from the automated container terminal of Shanghai Yangshan Port Phase IV, Obio Technology (Shanghai) Corp., Ltd. and Aplos Machines Manufacturing (Shanghai) Co., Ltd. (company profiles attached). The event’s agenda is as follows:
08:15 - 08:30 Gather at 200, Renmin Avenue, for departure
10:30 - 11:30 The automated container terminal of Shanghai Yangshan Port Phase IV
12:30 - 13:00 Working lunch (3888, Canghai Road, Fengxian District)
13:00 - 14:00 Obio Technology (Shanghai) Corp., Ltd. (3888, Canghai Road, Fengxian District)
14:30 - 15:30 Aplos Machines Manufacturing (Shanghai) Co., Ltd.
Kindly reminder: Since Yangshan Port Terminal is a no-fly zone for drones, please do not use drones for aerial photography.
Please kindly inform us of the media unit, the reporter’s name, mobile phone number in an email to touchshanghai@126.com before September 11, 2023.
Contact: Xu Peizhi, 18019788613
Information Office of Shanghai Municipality
September 8, 2023
Company Profiles
1.Shanghai Yangshan Port
Shanghai Yangshan Deepwater Port embarked on its official inauguration on December 10, 2005, with the completion of its phase V section. In recent years, the container transportation operations at Shanghai Port have exhibited a consistent pattern of rapid and stable growth. In the year 2022, the container throughput at Shanghai Port surpassed 47.3 million TEUs, securing its position as the world’s foremost port for the 13th consecutive year. The UNCTAD’s liner shipping connectivity index has consistently placed Shanghai Port at the pinnacle of global rankings for 12 consecutive years. This accomplishment underscores Shanghai Port’s innate strength and remarkable resilience. Furthermore, in the latest Xinhua-Baltic International Shipping Centre Development Index Report, Shanghai has ascended to a prestigious spot among the world’s top three. The primary highlights are as follows:
(1) Digital Transformation
The automated terminal of Yangshan Phase IV has taken pioneering steps by introducing a state-of-the-art digital twin system, heralding the development of an all-encompassing digital operations management platform that spans the entirety of the Shanghai Port and its eight container terminals. This milestone achievement marks the realization of a “three mapping in one” concept, namely electronic waterway mapping, coastline mapping, and berth mapping. Additionally, substantial progress has been made in establishing a comprehensive digital twin base, covering 70 square kilometers within the core section of the Huangpu River and 30 square kilometers in the eastern section of the Suzhou Creek. Furthermore, efforts to expedite the development of digital twin technology within the aviation sector are well underway, aimed at enhancing the intelligence of airport operations and management systems. The coordination of regional ports and shipping infrastructure is progressing methodically, facilitating information sharing and fostering collaborative commerce within the container river-ocean combined transport network along the Yangtze River. In a pioneering feat, the world’s first large-scale intelligent container ship, the “Lotus,” has been successfully built. This vessel boasts intelligent features within its engine room, energy efficiency systems, and navigation capabilities.
(2) Advancements in Intelligence
The Yangshan Deepwater Port Phase V stands as the world’s largest and most automated container terminal. The pivotal technologies pioneered here have found application in more than 10 terminals both domestically and internationally. Yangshan Port’s intelligent heavy trucks have notched up “four remarkable breakthroughs”: from initial road testing to successful demonstration operations, from single-vehicle intelligence to vehicle-road coordination, from independent platform deployment to system-wide integration, and from technology research and development to commercially viable exploration. A total of nearly 200,000 TEUs have been transported. Yangshan Port has further cemented its status as a trailblazer by becoming the first fully paperless port in China for all aspects of container business operations, achieving a 100% paperless operation rate. Global Shipping Business Network (GSBN) has revolutionized the import container document processing landscape, reducing the average processing time from a range of 24-48 hours to under 4 hours. Additionally, the concerted efforts towards the development of the Shanghai International Container Transportation Service Platform (container transport MaaS) have yielded a user-friendly system that offers “one-stop information inquiry” and streamlines “one-stop public services.”
(3) Sustainable Green Initiatives
Since the inception of the innovative to build the shipping center, there has been a steadfast commitment to optimizing port transportation and fostering an eco-friendly energy structure. In terms of the collecting and dispatching system, the proportion of containers transshipped reached 53.5% in 2022, an all-time high record. Furthermore, sea-rail combined transport for containers achieved a total volume of 576,000 TEUs, a year-on-year increase of 38%. In terms of the energy structure, within the domain of non-road mobile machinery, 49% now comprises clean energy and new energy equipment. Additionally, the port area boasts a network of 65 shore power facilities, strategically placed across five distinct types of specialized berths, achieving a coverage rate of 79%. Moreover, Shanghai Ports pioneering LNG ship-to-ship operation has become a standardized practice. In parallel, various green energy projects, including shore power, photovoltaic systems, and wind power, have been systematically rolled out across the port area.
In the future, Shanghai Port is poised to expedite the convergence of informatization, intelligence, and on-site production. This commitment will be realized through a series of pioneering initiatives, including the modernization and revitalization of conventional container terminals and the piloting of smart heavy trucks at Yangshan Port. Furthermore, the port will actively delve into the fusion of cutting-edge technologies such as blockchain, artificial intelligence, and big data, seeking their practical application across port production, operations, and management.
2.Obio Technology (Shanghai) Corp., Ltd.
Obio Technology (Shanghai) Corp., Ltd., founded in March 2013, is a pioneering biotech firm dedicated to advancing the realm of gene therapy. Our core focus includes foundational gene therapy research, the development of gene therapy vectors, gene function investigations, and an array of contract research organization (CRO) services, ranging from drug target exploration to drug efficacy studies. We also offer contract development and manufacturing organization (CDMO) services, including process development and testing, IND-CMC pharmaceutical research, and the GMP production of clinical samples.
Since its inception, the company has been steadfast in its commitment to the ethos of harmonizing resources to serve the life sciences. Guided by core values on customer-centricity, operational efficiency, pursuit of excellence, innovation and breakthroughs, integrity and pragmatism, we have experienced substantial growth and evolved into a cutting-edge enterprise that seamlessly integrates three key developmental dimensions in the realm of gene therapy: gene function basic research services, incubation of cell and gene therapy medications, and commercial-scale production services for clinical-grade cell and gene therapy drugs. Through nearly a decade of relentless dedication, Obio has garnered numerous accolades and qualifications, including recognition as a “Shanghai Science and Technology Little Giant Enterprise,” a “Shanghai Specialized and Sophisticated Enterprise,” a “Shanghai Patent Work Pilot Demonstration Enterprise,” a “Shanghai Enterprise Technology Center,” a “Shanghai Key Service Unicorn Enterprise,” a “Shanghai Customs Innovation Pioneer Demonstration Enterprise,” a “Shanghai Small- and Medium-sized Enterprise Technology Innovation and Quality Service Agency,” a “Pudong New Area Large Enterprise Open Innovation Center,” and a “Pudong New Area Enterprise R&D Institution,” among others. At present, our team comprises over 700 professionals, with over 50% dedicated to technical research and development. More than 30% of our workforce holds master’s degrees or higher qualifications. Our subsidiary companies include Obio Neuron (Shanghai) Biotechnology Co., Ltd., Obio Smart Manufacturing (Shanghai) Gene Technology Co., Ltd., Obio Xinchuang Biotechnology Research and Development (Shanghai) Co., Ltd., and Obio Jiuhe (Shenzhen) Gene Technology Co., Ltd.
With the mission of “Enable Gene Therapy for Better Life,” the company has focused on the research and development of viral vectors and the development of large-scale production processes to foster the development technology of gene therapy vectors. The company specializes in two core technology clusters, namely vector development technology and quality control technology for gene therapy, to establish a large-scale, highly flexible GMP production system suitable for a variety of gene drugs, versatile enough to cater to a wide spectrum of gene-based drugs. Our offerings encompass: 1) Vector products, including plasmids, adeno-associated viruses, and lentiviruses; 2) oncolytic virus products, such as oncolytic herpes viruses and oncolytic pox viruses; 3) comprehensive technical research, process development, and GMP production services catering to cell therapy products, CAR-T therapies.
The company currently boasts a robust network of over 9,000 CRO collaborative partners and nearly 150 CDMO collaborators. We take pride in holding 23 authorized invention patents within our two core technology domains, along with 59 distinct trademark registrations and 6 copyrighted assets. Moreover, we have established a state-of-the-art suite of in-house platforms, including molecular biology, experimental-grade virus vector packaging, cell function research, SPF-level animal experimentation, clinical-grade gene therapy vector and cell therapy process development, and quality control technology research platforms, among others.
Obio boasts an expansive research and development facility spanning over 5,000 square meters, a Gene Therapy Vector GMP Production Center exceeding 10,000 square meters, and a substantial investment of over 1.6 billion yuan to establish Obio Intelli-M. This sprawling, 80,000-square-meter facility is situated in the Lingang New Area of the China (Shanghai) Pilot Free Trade Zone, serving as an intelligent manufacturing precision medical industry hub. Obio Intelli-M project strategically leverages its location near the port to create an industrialized production hub for gene therapy and cell therapy medications. This production center adheres rigorously to international GMP standards, catering to the clinical and trial requirements of various viral and cellular products, as well as enabling commercial drug production. Furthermore, it will feature a cutting-edge detection technology platform for recombinant virus and cell-based drugs, establishing stringent quality benchmarks for related medications. Our platform is uniquely positioned to offer CDMO/CMO services for gene and cell therapy ventures. With world-class infrastructure and a robust GMP quality management system, this platform empowers the acceleration of gene therapy’s clinical applications, reduces drug production costs, enhances the accessibility of gene and cell therapy products, and bridges the domestic gap in this crucial field.
With the introduction and active execution of Shanghai’s 14th Five-Year Development Plan and the ongoing expansion of the “Innovative Medicines” strategic emerging industries in Pudong New Area, Obio remains steadfast in its commitment to delivering specialized services. Our aim is to establish a globally leading gene and cell therapy CXO conglomerate, expediting progress across fundamental research, drug discovery, pharmaceutical research, clinical trials, and commercialization in the field of gene therapy. We are dedicated to advancing the gene therapy industry, ultimately contributing to the enhancement of human health and well-being.
3. Aplos Machines Manufacturing (Shanghai) Co., Ltd.
Aplos Machines Manufacturing (Shanghai) Co., Ltd. is a technology-driven company that specializes in designing and producing mid to high-end CNC machine tools using direct-drive technology. We are dedicated to the field of metal cutting and serve a diverse range of manufacturing industries including civil aviation, mold-making, compressors, engineering machines, medical equipment, semiconductor, and the automotive industry.
Our highly-trained and innovative R&D team consists of over 60 engineers based in Shanghai and Singapore. They are experts in machine structural design, advanced Mechatronic systems, motion control, automation solutions, Industrial IoT, and machining technologies.
At Aplos Machines, we offer a completely new machine tool blueprint to China's manufacturing sector. Our products are engineered to deliver higher efficiency and accuracy, longer lifespan, and the ability to handle heavy cutting, ultra high-speed cutting, and micro-level cutting. We provide a revolutionary metal-cutting solution that caters to the evolving needs of the manufacturing industry.
Application Status
| 04-16 | 21315227 | Processing |
| 03-12 | 21315226 | Processing |
| 09-26 | 21315225 | Processing |
Inquiry Status
| 02-29 | 02131558 | Received |
| 03-06 | 02131557 | Received |
| 11-14 | 02131556 | Received |
FAQ
Q: Q: Is there a place where I can get...
A: A: Log on to http://touch.shio.gov....
A: A: Log on to http://touch.shio.gov....
Q: Q: What is the easiest way to set u...
A: A: 1. Log on to http://touch.shio.g...
A: A: 1. Log on to http://touch.shio.g...
Q: Where can I get an English map of S...
A: English maps of Shanghai are availa...
A: English maps of Shanghai are availa...